The depth of our knowledge and expertise with antisense technology together with our strong financial position provides us the flexibility to partner our drugs at what we believe is the optimal time to maximize the near- and long-term value of our drugs. We have distinct partnering strategies that we employ based on the specific program, therapeutic area and the expertise and resources our potential partners may bring to the collaboration. For some drugs, we may choose to develop and commercialize them through wholly owned subsidiaries like Akcea. For other drugs, we may form partnerships that enable us to leverage our partner’s global expertise and resources needed to support large commercial opportunities.
We have established alliances with a cadre of leading global pharmaceutical companies that are working alongside us in developing our drugs, advancing our technology, preparing to commercialize our drugs and selling our drugs. Our partners bring substantial resources and expertise that augment and build upon our internal capabilities.
We have strategic partnerships through which we can broadly expand our drug discovery efforts to new disease targets in specific therapeutic areas, as well as partnerships with companies that bring significant expertise and global resources to develop and potentially commercialize drugs for a particular therapeutic area. We also form early stage research and development partnerships that allow us to expand the application of our technology to new therapeutic areas. Lastly, we also work with a consortium of companies, referred to as satellite companies, that can exploit our drugs and technologies outside our primary areas of focus.
Through our partnerships, we have created a broad and sustaining base of potential R&D revenue in the form of license fees, upfront payments and milestone payments while spending prudently to advance our pipeline and technology. Since 2007, we have received more than $1.9 billion in cash from upfront and licensing fees, equity purchase payments, milestone payments and research and development funding from our partnerships. We have the potential to earn nearly $13 billion in future milestone payments and licensing fees from our current partnerships. We also have the potential to share in the future commercial success of our inventions and drugs resulting from our partnerships through earn out or royalty arrangements. With the approval of SPINRAZA by the U.S. FDA for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients, we are adding commercial revenue from SPINRAZA royalties from our partner Biogen to our existing R&D revenue base. Looking forward, we have the potential to increase our commercial revenue from SPINRAZA royalties if Biogen achieves marketing authorization in additional countries. We also have the potential to further increase our commercial revenue with volanesorsen product sales and IONIS-TTRRx royalties.
Akcea Therapeutics, Inc.
In late 2014, we formed Akcea Therapeutics, Inc. to focus on developing and commercializing our drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, including volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx. Moving our lipid assets into a company we own allows us to retain substantial value from these drugs and ensures our core focus remains on innovation.